AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.5 |
Market Cap | 75.90M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.13 |
PE Ratio (ttm) | -4.2 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 0.8 |
Volume | 48,304 |
Avg. Volume (20D) | 137,311 |
Open | 0.47 |
Previous Close | 0.50 |
Day's Range | 0.47 - 0.55 |
52-Week Range | 0.33 - 1.30 |
Beta | undefined |
About XTNT
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect ...
Analyst Forecast
According to 1 analyst ratings, the average rating for XTNT stock is "Strong Buy." The 12-month stock price forecast is $3, which is an increase of 449.45% from the latest price.
Next Earnings Release
Analysts project revenue of $30.90M, reflecting a 9.93% YoY growth and earnings per share of -0.01, making a -66.67% decrease YoY.
2 months ago · seekingalpha.com
Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call TranscriptXtant Medical Holdings, Inc. (NYSE:XTNT ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conferenc...